Daylife Select
A point & click tool to create dynamic content portals. Learn More »
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
Today Simon Varcoe Please Login to read the full article. Full Article at Scrip News
Trellis Bioscience Inc. sold a worldwide exclusive license that allows AstraZeneca plc’s MedImmune unit to develop and commercialize antibodies focused on respiratory syncytial virus. Full Article at San Francisco Business Times
From left, Operations MedImmune Executive Vice President for Operations Dr. Ben Machielse; Phillip Hosbach, vice president, Immunization Policy and Government Relations Sanofi Pasteur; Texas Department of State Health Services Commissioner David Lakey;... View Photo »
MedImmune is pleased to report these findings that demonstrate that the safety profile and immunogenicity of our nasal spray vaccine for the 2009 H1N1 virus is, as expected, similar to our seasonal influenza vaccine
Trellis Bioscience, Inc. Full Article at Biospace
Trellis Bioscience, Inc. announced today the granting of a worldwide exclusive license to MedImmune, LLC, the global biologics unit of AstraZeneca, to develop and commercialize Trellis’ antibodies directed against the respiratory syncytial virus (RSV). Full Article at News-Medical.net
GlaxoSmithKline PLC has just received approval from the World Health Organization (WHO) for one of its swine flu vaccines. Full Article at Injury Board
From left, CSL Biotherapies, Inc. View Photo »
"Doctors' group opposes all vaccine mandates." Full Article at Huffington Post
Main Category: Cancer / Oncology Article Date: 29 Nov 2009 - 0:00 PST email to a friend printer friendly view / write opinions rate article A PhD student at The Institute of Cancer Research (ICR) has won an Europe-wide competition for her... Full Article at Medical News Today
There are no results for this module. Edit this module to change the search term used to query Wikipedia
From left, Operations MedImmune Executive Vice President for Operations Dr. Ben Machielse; Phillip Hosbach, vice president, Immunization Policy and Government Relations Sanofi Pasteur; Texas Department of State Health Services Commissioner David Lakey; and Trust for America's Health Exe...
View Photo »From left, CSL Biotherapies, Inc.
View Photo »MedImmune is pleased to report these findings that demonstrate that the safety profile and immunogenicity of our nasal spray vaccine for the 2009 H1N1 virus is, as expected, similar to our seasonal influenza vaccine
At MedImmune, our mission is to develop and deliver medicines that change lives, and we are proud that our innovative LAIV technology may help protect the public from the threat of 2009 H1N1 influenza ... We will continue to work collaboratively with the U.S. government and public health authorities to ...
There are no results for this module. Edit the module to change the search term used to query Twitter.
